Resverlogix Corp
TSX:RVX

Watchlist Manager
Resverlogix Corp Logo
Resverlogix Corp
TSX:RVX
Watchlist
Price: 0.1 CAD 5.26% Market Closed
Market Cap: 28.7m CAD

Resverlogix Corp
Change in Working Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Resverlogix Corp
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Resverlogix Corp
TSX:RVX
Change in Working Capital
$31k
CAGR 3-Years
-81%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Change in Working Capital
-$5.7m
CAGR 3-Years
N/A
CAGR 5-Years
-64%
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Change in Working Capital
-$4.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Change in Working Capital
$7.2m
CAGR 3-Years
N/A
CAGR 5-Years
76%
CAGR 10-Years
12%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Change in Working Capital
-$2.4m
CAGR 3-Years
-49%
CAGR 5-Years
N/A
CAGR 10-Years
17%
Spectral Medical Inc
TSX:EDT
Change in Working Capital
CA$160k
CAGR 3-Years
13%
CAGR 5-Years
-53%
CAGR 10-Years
-7%
No Stocks Found

Resverlogix Corp
Glance View

Market Cap
28.7m CAD
Industry
Biotechnology

Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.

RVX Intrinsic Value
Not Available

See Also

What is Resverlogix Corp's Change in Working Capital?
Change in Working Capital
31k USD

Based on the financial report for Dec 31, 2024, Resverlogix Corp's Change in Working Capital amounts to 31k USD.

What is Resverlogix Corp's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
-81%

Over the last year, the Change in Working Capital growth was -95%. The average annual Change in Working Capital growth rates for Resverlogix Corp have been -81% over the past three years .

Back to Top